Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Oncology Group
Essen Biotech
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
University of Wisconsin, Madison
AVM Biotechnology Inc
Barbara Ann Karmanos Cancer Institute
Miltenyi Biomedicine GmbH
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
University of Virginia
Norwegian University of Science and Technology
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
AbbVie
M.D. Anderson Cancer Center
Bristol-Myers Squibb
National Institute of Allergy and Infectious Diseases (NIAID)
Northwestern University
M.D. Anderson Cancer Center
Celgene
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
University of Texas Southwestern Medical Center
Vanderbilt-Ingram Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
OHSU Knight Cancer Institute